Table 2. Extrapulmonary TB localizations according to HIV status.

	HIV-infected	HIV-uninfected	HIV-unknown	Total
	(n = 38)(n = 46)(n = 67)(n = 151)
	Percentage (95% CI)
Cervical lymphadenopathy	5.3 (1.4−17.6)	30.4 (18.9–45.1)	32.8 (22.6–45.0)	25.2 (18.8–32.8)
Mediastinal lymphadenopathy	7.9 (2.7−21;1)	0.0 (0.0–8.0)	0.0 (0.0–5.6)	2.0 (0.7–5.8)
Pleural	27.8 (13.7−44.3)	26.1 (15.4–40.6)	19.4 (11.6–30.7)	23.2 (17.1–30.7)
Abdominal	29.0 (16.8−45.1)	17.4 (9.0–31.0)	7.5 (3.2–16.5)	15.9 (10.8–22.7)
CNS	15.8 (7.3−30.8)	15.2 (7.5–28.5)	0.0 (0.0–5.6)	8.6 (5.1–14.3)
Disseminated	10.5 (4.1−27.5)	2.2 (0.4–11.6)	0.0 (0.0–5.6)	3.3 (1.4–7.6)
Skeletal	5.3 (1.4−17.6)	2.2 (0.4–11.6)	38.8 (27.9–51.0)	19.2 (13.6–26.4)
Genito–urinary	0.0 (0.0–9.5)	2.2 (0.4–11.6)	0.0 (0.0–5.6)	0.7 (0.1–3.8)
Skin	0.0 (0.0–9.5)	0.0 (0.0–8.0)	2.2 (0.4–11.6)	0.7 (0.1–3.8)
Rectal	0.0 (0.0–9.5)	2.2 (0.4–11.6)	0.0 (0.0–5.6)	0.7 (0.1–3.8)
Pericarditis	0.0 (0.0–9.5)	2.2 (0.4–11.6)	0.0 (0.0–5.6)	0.7 (0.1–3.8)

TB: tuberculosis, CNS: central nervous system; TB: HIV: Human Immunodeficiency Virus; CI: confidence interval.